Inflammatory Bowel Disease Treatment Market: Information by Drug Class (TNF Inhibitors, Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease) Distribution Channel (Hospital Pharmacy), End-User (Hospitals & Clinics)—Forecast 2027
|ID: VPR/HC/1086||Publishing Year: January 2022||Pages: 108||Format:|
Inflammatory Bowel Disease Treatment Market Overview:
The Inflammatory Bowel Disease Treatment Market is expanding due to causes such as the rising prevalence of Crohn's disease and ulcerative colitis, increased government financing for Inflammatory Bowel Disease Research, and medical technological developments. In addition, the growing popularity of pre-biotic and pro-biotic dietary products, as well as an increasing number of medications in clinical trials, are projected to contribute to market growth throughout the evaluation period.
The market for Inflammatory Bowel Disorders is predicted to grow, but it will be constrained by greater capital expenditures for drug discovery, insufficient clinical efficacy of therapy, and strict drug regulatory policies.
- Abbott Laboratories
- Valeant Pharmaceuticals International
- Novartis AG
- Janssen Biotech, Inc.
- Alkem Laboratories Limited
- AbbVie, Inc.
- UCB Inc
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Pfizer Inc.
- Allergan plc
A couple of the primary drivers for the IBD industry are people's irregular eating habits and poor lifestyles, as well as growing pollution levels. Increased alcohol intake and cigarette smoking are also major factors fueling the IBD Market.
New approaches for diagnosing IBD have emerged as a result of ongoing R&D efforts, reducing the need of previous diagnostic methods. One of the major issues facing the IBD business is the high initial capital necessary for the construction of IBD diagnosis centres.
On the basis of drug class, disease indication, distribution channel, and end-user, the Global Inflammatory Bowel Disease Treatment Market has been segmented. The market has been divided into TNF inhibitors, aminosalicylates, immunomodulators, and corticosteroids based on pharmacological class.
The market has been divided into ulcerative colitis and Crohn's disease based on disease indication.
The market has been divided into three segments based on distribution channels: hospital pharmacy, retail pharmacy, and online pharmacy.
The market has been divided into hospitals and clinics, as well as other end-users.
In North America, the market for IBD (ulcerative colitis and Crohn's disease) treatments is fueled by ongoing research and development by major pharmaceutical companies, as well as increased government funding to support the development of new medicines. Key corporations in the region are concentrating on the development of branded medications, while TMR's research suggests that the development of biosimilar goods will expand in developing countries in Asia Pacific. Several nations, including Australia, Japan, India, China, South Korea, and Malaysia, are creating regulatory norms and testing requirements for the approval of biosimilar pharmaceuticals in order to ensure their efficacy.
Type Here for table of content.